It was published on Jan. 6 in JAMA Internal Medicine. DoxyPEP is a new strategy for preventing STIs that involves taking a dose of doxycycline, a common and well-tolerated antibiotic medication, ...

Both studies in JAMA Internal Medicine supported the rising profile of doxyPEP as a way to counter the epidemic of syphilis, gonorrhea, and chlamydia infections, even if the data ...

While the use of PrEP has helped drop the rates of HIV infections, instances of syphilis and chlamydia among queer men have been skyrocketing, but a new study shows that doxyPEP may be the answer to ...

The early rollout of doxyPEP — a dose of the antibiotic doxycycline after sex — has contributed to a decline in sexually transmitted infections in Northern California, according to a pair of studies ...

This is one of the first real-world studies to show the effectiveness of the tactic called doxyPEP, for doxycycline post-exposure prophylaxis, researchers said. Related 20% of people aged 15 to 49 ...

Quarterly syphilis rates decreased from 1.7% prior to doxyPEP availability to 0.3% afterward, while quarterly chlamydia rates declined from 9.6% to 2%. Quarterly gonorrhea infections dropped from 10.2 ...

Doxycycline postexposure prophylaxis (doxyPEP) initiation is associated with decreases in sexually transmitted infections (STIs).

Doxycycline postexposure prophylaxis has the potential to substantially reduce real-world population-level incidence of ...

A new treatment for sexually-transmitted diseases seems to be slowing an STI epidemic — but not everyone can get it ...

It tends to be less effective at preventing gonorrhoea. DoxyPEP can be taken by those living with HIV and people who are HIV-negative. This approach may not be effective for cisgender women or people ...

This is one of the first real-world studies to show the effectiveness of the tactic called doxyPEP, for doxycycline post-exposure prophylaxis, researchers said. “Interventions that are effective ...